Breaking News

Kindeva, Orbia Partner on Low GWP Propellant Conversion

Aims to facilitate conversion of pMDI products to the lower GWP propellent 152a and progress them through clinical development.

Kindeva Drug Delivery, a global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corp.’s Fluorinated Solutions business Koura, a company involved in the development, manufacture, and supply of fluoroproducts and technologies, entered a co-development collaboration for the conversion from existing marketed pressurized metered dose inhaler (pMDI) products to Koura’s more sustainable and environmentally-conscious medical...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters